TipRanks
55% OFF
PC:PEPRO

PeproMene Bio Inc

15375 Barranca Pkwy Suite A211 Irvine, California 92618, ushttps://pepromenebio.com/Therapeutics

PeproMene Bio Inc is a biotechnology company focused on developing targeted immunotherapies for cancer and autoimmune diseases. The company is advancing its BAFF-R CAR T cell therapy, PMB-CT01, specifically for patients with relapsed or refractory follicular lymphoma. PeproMene Bio aims to address unmet medical needs in the treatment of B-cell Non-Hodgkin Lymphoma through innovative cellular therapies.

Leadership & Board

Current Number of Employees
10
Current LinkedIn Followers
698

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$11M
Total Funding Rounds
1
Latest Funding Amount
$11M
Latest Funding Round
Investment
Post-Money Valuation
―

Employee Trend

PeproMene Bio Inc had 10 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.

10Latest Employee Count
0(0.00%)Week-Over-Week Change
05101520Jan 19, 2026Feb 02, 2026Feb 16, 2026Mar 02, 2026Mar 16, 2026Mar 30, 2026Apr 13, 2026May 04, 2026May 18, 2026Jun 01, 2026Jun 15, 2026Jun 29, 2026Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026

Social Trend

PeproMene Bio Inc had 698 followers as of October 12, 2026. The number of followers increased by 1 (0.14%) week-over-week.

698Latest Followers Count
1(0.14%)Week-Over-Week Change
0200400600800Jan 19, 2026Feb 02, 2026Feb 16, 2026Mar 02, 2026Mar 16, 2026Mar 30, 2026Apr 13, 2026May 04, 2026May 18, 2026Jun 01, 2026Jun 15, 2026Jun 29, 2026Jul 20, 2026Aug 03, 2026Aug 17, 2026Aug 31, 2026Sep 14, 2026Sep 28, 2026Oct 12, 2026

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Aug 14, 2025Investment$11.00M―

Investors

Investor NameFunding Round
Institute for Follicular Lymphoma InnovationInvestment

Similar Companies

A snapshot of private companies similar to PeproMene Bio Inc, helping you discover and navigate related company profiles.

Related News and Analysis